IL-36 bispecific monoclonal antibody(Almirall)

N/A

Report date: 2023/11/07 17:36:48

Base Information

Drug NameIL-36 bispecific monoclonal antibody(Almirall)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionInterleukin-36 receptor modulators
TargetsInterleukin-36 receptor
Therapy Area/IndicationsSkin Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator Companies23andme IncAlmirall Sa
China Registration ClassN/A

Develop Information

Active Companies23andme IncAlmirall Sa
Inactive CompaniesN/A
Active IndicationsSkin Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A